

ANTIGENICS INC /DE/
Form NT 10-Q
May 11, 2006
(Check One):

UNITED STATES

OMB APPROVAL
OMB Number: 3235-0058

Expires: April 30, 2009

Estimated average burden
hours per response . . . 2.50

SEC FILE NUMBER

0-29089

CUSIP NUMBER

037032109

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

Form 10-K

Form 20-F

Form 11-K

Form 10-Q

Form 10-D

Form N-SAR

Form N-CSR

For Period Ended: March 31, 2006

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: _____

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I REGISTRANT INFORMATION

ANTIGENICS INC.

Full name of Registrant

Former Name if Applicable

630 Fifth Avenue, Suite 2100
Address of principal executive office (*Street and Number*)

New York, NY 10111
City, state and zip code

PART II RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
 - (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
- X

PART III NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has been working diligently to complete its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006. At this time, the Registrant has not had sufficient time to complete the accounting for its stock-based compensation under the newly issued fair value recognition provisions of Financial Accounting Standards Board, Statement of Financial Accounting Standards No. 123R, *Share-Based Payment*, which was adopted by the Registrant this quarter, without incurring unreasonable effort or expense. The Registrant expects to file its completed report on or before May 15, 2006.

PART IV OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification
Peter Thornton (212) 994-8200

(Name) (Area Code) (Telephone Number)

Edgar Filing: ANTIGENICS INC /DE/ - Form NT 10-Q

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12

months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

ANTIGENICS INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 11, 2006

By /s/ Peter Thornton

Peter Thornton, Chief Financial Officer